| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 2, 2026Next | Q3 2026 | Before market open | 0.30 | 3.94 B |
Aug 27, 2026
Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...
Aug 24, 2026
Kenvue Inc. upgraded to a soft buy as the Kimberly-Clark Corporation merger looks likely. Click for this updated look at KVUE and KMB as they seek to join.
In a challenge brought by Kenvue Inc., BBB National Programs’ National Advertising Division determined that Hims & Hers Health, Inc. provided a reasonable basis for its comparative efficacy claim. However, the National Advertising Division (NAD) recommended that it modify or discontinue other claims regarding doctor-trusted ingredients, dermatologist recommendations, safety and side effects.New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Kenvue Inc., BBB National Progra
Kenvue Inc.âs KMB buyout faces China SAMR Phase 2 antitrust review. Click for more on KVUE and how this affects whether you should invest in KVUE stock.
Aug 21, 2026
Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...
In August 2026, Kenvue’s Zyrtec brand launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that forms a gel barrier in the nose within minutes to help block common airborne allergens like pollen, pet dander, and dust for up to six hours in adults and children aged 12 and older. This first-of-its-kind, HPMC-based spray expands Zyrtec’s toolkit toward proactive allergen defense, signaling Kenvue’s push into drug-free, preventative allergy solutions. We’ll now examine how this new...
Aug 20, 2026
Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...
Hygiene and health company Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity's position as a market leader in feminine care in Latin America.
Aug 19, 2026
https://www.essity.com/media/press-release/essity-acquires-feminine-care-business-in-brazil/9dd724cebbb532f5/
Aug 14, 2026
- Reuters
Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]
Aug 12, 2026
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Kimberly-Clark looks good, supported by a strong innovation pipeline, international growth, and the Kenvue acquisition. See why I rate KMB stock a Buy.
Aug 11, 2026
UBS analyst Peter Grom maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $20 to $19.
Aug 7, 2026
Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.
Aug 6, 2026
Sales and earnings increased across Kenvue's portfolio, but tariffs, inflation and currency costs reduced profitability.
Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.
Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with...
